Clinical Trial Update: A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety of GRF6021 infusions in Parkinson's disease with cognitive impairment; trial completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• GRF6021

Snippet

Sponsor: Alkahest, Inc. | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-05-09